Viyash Scientific Limited (VIYASH)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 15 July 2026

₹280.45

🎯 Key Takeaways

Viyash Scientific Limited is transitioning from a period of financial distress to a phase of operational stabilization and strategic growth, marked by margin expansion, deleveraging, and inorganic expansion plans. The company has moved past negative earnings trends seen in FY23 and early FY24, with recent quarters showing revenue growth and improved profitability.
Revenue grew 6% QoQ to ₹391 in Q3FY25.
⚠️ Regulatory scrutiny remains present, as evidenced by the SEBI administrative warning for SDD maintenance lapses, which, while non-financial, signals c

Market Cap

₹9,809

P/E Ratio

488.1

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About VIYASH 📊 Interactive Charts

📖 The Story

Viyash Scientific Limited is transitioning from a period of financial distress to a phase of operational stabilization and strategic growth, marked by margin expansion, deleveraging, and inorganic expansion plans. The company has moved past negative earnings trends seen in FY23 and early FY24, with recent quarters showing revenue growth and improved profitability. Management is actively building a sustainable platform through cost discipline and strategic acquisitions, positioning for long-term value creation in the pharmaceutical sector.

📰 What's Happening

In FY26, Viyash reported revenue of ₹34,203 crores, up 13.8% YoY, with EBITDA rising 59.6% YoY to ₹7,025 crores and net debt reduced to ₹4,511 crores. The company highlighted merger synergies beginning to reflect in financials and strong Q4 performance as drivers of improvement. Management emphasized ongoing evaluation of selective inorganic opportunities to strengthen its platform and advance its growth roadmap for FY27. Additionally, all three resolutions at the AGM on June 28, 2026, were passed with overwhelming support, including the appointment of two non-executive directors and approval of a CEO performance incentive, underscoring shareholder confidence in leadership continuity.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	367	333	346	329	361	390	369	391
Operating Profit	-63	-31	25	30	32	45	39	40
OPM %	-0.9%	-2.5%	4.4%	6.8%	8.9%	10.8%	10.6%	8.8%
Net Profit	-92	-35	-7	11	1	9	6	6
EPS	₹-3.77	₹-1.40	₹-0.34	₹0.33	₹-0.04	₹0.26	₹0.10	₹0.14

The company's financial trajectory shows a clear inflection point from FY23 to FY26, with revenue growing from ₹367 crores in Q4FY23 to ₹391 crores in Q3FY25, and EBITDA margin expanding from negative 0.9% to 8.8% over the same period. While quarterly profitability remains volatile, the trendline in EBITDA and net debt reduction reflects improving operational efficiency and capital structure management. The consistent YoY growth in revenue and EBITDA in FY26, despite macroeconomic headwinds, suggests that previously announced restructuring and integration efforts are beginning to yield results.

🔮 Management Outlook & What's Next

Management expressed confidence in future growth, stating they are 'excited about the product pipeline and growth roadmap for FY27' and actively evaluating 'selective inorganic opportunities' to further strengthen their platform. They emphasized that merger synergies are beginning to materialize and that the deleveraged balance sheet provides flexibility for strategic investments. While no formal financial guidance was provided in the filings, the tone was forward-looking, focusing on sustainable growth, operational excellence, and long-term value creation through both organic and inorganic means.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Sun Pharmaceutical Industries Limited	4.51 L Cr	41.3	20.3%	15.1%	0.03
Divi's Laboratories Limited	1.79 L Cr	72.4	22.1%	16.6%	0.00
Torrent Pharmaceuticals Limited	1.49 L Cr	80.1	—	—	—
Cipla Limited	1.16 L Cr	25.4	19.4%	14.6%	0.00
Dr. Reddy's Laboratories Limited	1.12 L Cr	20.0	19.7%	16.6%	0.12
Lupin Limited	1.04 L Cr	36.2	—	—	—
Mankind Pharma Limited	1.03 L Cr	49.2	—	—	—
Zydus Lifesciences Limited	1.02 L Cr	22.5	—	—	—
Aurobindo Pharma Limited	87,806	25.3	—	—	—
Laurus Labs Limited	71,455	356.8	—	—	—

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM CIPLA DRREDDY

⚠️ Risk Factors

1. Regulatory scrutiny remains present, as evidenced by the SEBI administrative warning for SDD maintenance lapses, which, while non-financial, signals compliance vulnerabilities. 2. Profitability remains sensitive to operational execution, given the volatility in OPM and net income across quarters, particularly in earlier periods. 3. Growth is increasingly reliant on merger synergies and inorganic expansion, which carry integration and execution risks. 4. High P/E multiple (488.1) reflects elevated valuation expectations, making the stock susceptible to earnings volatility and market sentiment shifts.

📋 Recent Filings

🧠 Analyst's Read

Viyash Scientific is undergoing a strategic turnaround, with improving financial metrics and shareholder confidence supporting its repositioning. The key watchpoints ahead are sustained margin expansion, successful integration of merger synergies, and execution of inorganic growth plans. Investors should monitor upcoming quarterly results and management's ability to deliver on growth commitments without compromising financial stability.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on VIYASH

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-15.

📡 Get AI alerts when VIYASH files new disclosures

Track VIYASH filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track VIYASH — Free

Free account · 2 AI queries/day